NGM Biopharmaceuticals, Inc. is a biopharmaceutical company with a focus on developing innovative treatments for liver and metabolic diseases, retinal diseases, and cancer. The company's pipeline includes product candidates such as Aldafermin and MK-3655, both of which are in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, as well as a range of products under development for the treatment of advanced solid tumors, geographic atrophy, and more. NGM Biopharmaceuticals, Inc. has also entered into research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. and a collaboration agreement with Merck & Co., Inc. to further advance the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Founded in 2007 and headquartered in South San Francisco, the company is at the forefront of driving innovation in the biopharmaceutical industry, with a strong commitment to developing breakthrough therapies that can help patients in need.